136 related articles for article (PubMed ID: 18727312)
1. The effect for oncology of the national coverage determination for erythropoiesis-stimulating agents.
Jorgenson JA
Manag Care Interface; 2008 Jul; 21(1):7-8. PubMed ID: 18727312
[No Abstract] [Full Text] [Related]
2. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
3. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
4. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
Yu JM; Shord SS; Cuellar S
J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
[TBL] [Abstract][Full Text] [Related]
5. CMS issues new conditions for coverage for ambulatory surgical centers.
Becker S; Walsh A; Higgins R
Health Care Law Mon; 2007 Nov; (11):2-7. PubMed ID: 18064752
[No Abstract] [Full Text] [Related]
6. Bariatric surgery coverage decision: opportunities and limitations.
Elmore BL; Phillips WT
Healthc Financ Manage; 2006 Oct; 60(10):52-4. PubMed ID: 17040030
[TBL] [Abstract][Full Text] [Related]
7. New process for making national coverage decisions in the Medicare program.
Tecnologica; 1999 Jun; ():7-8. PubMed ID: 10558576
[No Abstract] [Full Text] [Related]
8. Centers for Medicare & Medicaid Services telehealth coverage of MNT--what ADA members need to know.
Hager MH
J Am Diet Assoc; 2006 Apr; 106(4):513-6. PubMed ID: 16567144
[No Abstract] [Full Text] [Related]
9. Need help understanding Medicare or Medicaid?
Pa Health You; 2002; 105(2):12. PubMed ID: 16350776
[No Abstract] [Full Text] [Related]
10. Congressional oversight of Medicare program intensifies: a look at the factors surrounding the scrutiny and nephrology's response.
Blaser RE; Kliger AS
Adv Chronic Kidney Dis; 2008 Jan; 15(1):10-4. PubMed ID: 18155104
[TBL] [Abstract][Full Text] [Related]
11. Updated clinical practice guidelines on erythropoiesis-stimulating agents.
Silver SM
Clin Adv Hematol Oncol; 2007 Dec; 5(12):945-6. PubMed ID: 18277954
[No Abstract] [Full Text] [Related]
12. 15 new developments are already reshaping 2006 Medicare coverage.
Med Health; 2005 Dec; 59(44):1, 6-7. PubMed ID: 16353460
[No Abstract] [Full Text] [Related]
13. Medicare's revised clinical trial policy and clinical trial-related provisions of FDAAA: what is a sponsor to do?
Dobbins K; Scanlan K
Food Drug Law J; 2007; 62(4):695-708. PubMed ID: 18557226
[No Abstract] [Full Text] [Related]
14. Responding with a united voice to the Conditions of Coverage!
VanBuskirk S
Nephrol Nurs J; 2005; 32(3):266-7. PubMed ID: 16035469
[No Abstract] [Full Text] [Related]
15. Medicare issues long-awaited ASC CfCs.
OR Manager; 2008 Dec; 24(12):22-3. PubMed ID: 19119769
[No Abstract] [Full Text] [Related]
16. Changes in the Medicare coverage process.
Harris JA
Bull Am Coll Surg; 2000 Mar; 85(3):8-11. PubMed ID: 11349565
[No Abstract] [Full Text] [Related]
17. Section 1115 waivers and budget neutrality: using Medicaid funds to expand coverage.
Milligan C
State Coverage Initiat Issue Brief; 2001 May; 2(2):1-4. PubMed ID: 11887924
[No Abstract] [Full Text] [Related]
18. CMS: Medicare drug formularies to cover most HIV drugs.
AIDS Policy Law; 2005 Aug; 20(15):2. PubMed ID: 16136681
[No Abstract] [Full Text] [Related]
19. HCFA and expanded coverage of PET.
Coleman RE; Tesar R; Phelps M
J Nucl Med; 2001 Apr; 42(4):11N-12N. PubMed ID: 11458870
[No Abstract] [Full Text] [Related]
20. What's up with SCHIP?
Saunders JB
NCSL Legisbrief; 2008; 16(33):1-2. PubMed ID: 18717034
[No Abstract] [Full Text] [Related]
[Next] [New Search]
